Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINE 2: obrixtamig added to first-line platinum-based therapy for advanced pulmonary large-cell neuroendocrine carcinoma
2025-524345-28-00Phase 2Authorised
- Sponsor
- Technische Universität Dresden
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obrixtamig in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC), sponsored by Technische Universität Dresden. Primary endpoint: overall survival. Planned start Aug 2026; status: authorised.
02
Drugs
obrixtamig
03
Conditions
Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)
Beyond the preview
Go deeper on 2025-524345-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524345-28-00.